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Abstract
Background: Identification of risk factors of acute hepatitis C virus (HCV) infection in Egypt is crucial to develop
appropriate prevention strategies.
Methods: We conducted a case–control study, June 2007-September 2008, to investigate risk factors for acute HCV
infection in Egypt among 86 patients and 287 age and gender matched controls identified in two infectious
disease hospitals in Cairo and Alexandria. Case-patients were defined as: any patient with symptoms of acute
hepatitis; lab tested positive for HCV antibodies and negative for HBsAg, HBc IgM, HAV IgM; and 7-fold increase in
the upper limit of transaminase levels. Controls were selected from patients’ visitors with negative viral hepatitis
markers. Subjects were interviewed about previous exposures within six months, including community-acquired
and health-care associated practices.
Results: Case-patients were more likely than controls to have received injection with a reused syringe (OR=23.1,
CI 4.7-153), to have been in prison (OR=21.5, CI 2.5-479.6), to have received IV fluids in a hospital (OR=13.8,
CI 5.3-37.2), to have been an IV drug user (OR=12.1, CI 4.6-33.1), to have had minimal surgical procedures
(OR=9.7, CI 4.2-22.4), to have received IV fluid as an outpatient (OR=8, CI 4–16.2), or to have been admitted to
hospital (OR=7.9, CI 4.2-15) within the last 6 months. Multivariate analysis indicated that unsafe health facility
practices are the main risk factors associated with transmission of HCV infection in Egypt.
Conclusion: In Egypt, focusing acute HCV prevention measures on health-care settings would have a beneficial
impact.
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Background
Chronic hepatitis C virus (HCV) infection is a major
cause of chronic liver disease worldwide. The World
Health Organization (WHO) estimates that 3% of the
world’s populations, approximately 170 million people
are infected with HCV. Approximately 60% of persons
with HCV infection develop chronic or lifelong infection
with HCV. Persons with chronic HCV infection are at
increased risk for development of chronic liver disease,
including 5-20% who may develop cirrhosis. It is esti-
mated that approximately 5% of infected persons may
die from the consequences of long term infection (liver
cancer or cirrhosis) [1]. HCV is spread primarily by
direct contact with human blood. Risk factors most
frequently associated with HCV transmission are trans-
fusion of unscreened blood, injection drug use, unsafe
injections, and other iatrogenic health care procedures.
The development of diagnostic assays to screen blood
and blood products has resulted in a remarkable reduc-
tion in transfusion-associated HCV infection in many
developed countries [2]. Similarly, the implementation of
standard precautions to prevent occupational exposure
to blood has resulted in a decrease in blood-borne patho-
gen transmission in the health care setting [3]. Since the
implementation of these measures, epidemiologic studies
indicate that injection drug use is the predominant mode
of transmission in developed countries [4].* Correspondence: salma.afifi.eg@med.navy.mil2Global Disease Detection and Response, U.S. Naval Medical Research Unit
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While, there are numerous studies documenting the
emergence of HCV as an important public health prob-
lem in developing countries, there are few studies charac-
terizing the epidemiology of HCV transmission in those
countries. Available studies suggest that HCV transmis-
sion is complex and that transfusion of unscreened
blood, unsafe injections, and invasive health-care proce-
dures remain important causes of disease transmission.
While transmission associated with injection drug use is
also a well-recognized risk factor, many studies suggest
that most HCV infections in the developing world are
attributable to health care-related exposures [5].
The epidemiology of HCV transmission in Egypt has
been the subject of intense study in the two decades
since HCV diagnostic assays became available. Several
studies have documented a prevalence of HCV antibodies
ranging from 6 to 20% in the general population [6,7].
It is generally accepted that the high prevalence of HCV
infection is in part attributed to parenteral antischistoso-
mal treatment campaigns that were conducted in the
1970s. However, epidemiologic studies suggest that HCV
continues to be transmitted at relatively high rates [8].
Monitoring the incidence of HCV infections is difficult
because most infections are asymptomatic and available
assays do not distinguish acute from chronic or resolved
infections [9]. Prospective cohort studies monitoring HCV
seroconversion among susceptible persons have identi-
fied incidence rates ranging from 3.1 to 5.2 per 100,000
[10,11]. Based on these studies, it is projected that
248,000 to 416,000 infections may occur each year in
Egypt.
Numerous epidemiologic studies have reported diverse
exposures associated with HCV infection in Egypt, in-
cluding unsafe injections, health care procedures, and
various community exposures. However, there are lim-
itations to the interpretation of these data since many
are based on HCV-infected persons identified in cross-
sectional seroprevalence surveys and not among patients
with newly acquired infections. Without well-designed
studies of patients with acute disease, it is challenging to
develop prevention strategies that are focused on the
most important sources of ongoing transmission. This
study is designed to identify risk factors among patients
with newly acquired HCV infection, focusing on various
healthcare and community-level practices. It is antici-
pated the results will inform health officials on key areas
to formulate strategies for the prevention of HCV trans-
mission in Egypt [12].
Methods
Between June 2007 and September 2008, case-patients
and controls were enrolled from two major infectious
disease hospitals in Cairo (Abassia Fever Hospital) and
Alexandria (Alexandria Fever Hospital). An eligible case-
patient was defined as any patient with signs and symp-
toms of acute hepatitis, including jaundice and the
following laboratory criteria: 1. Antibodies to HCV
(anti-HCV) (identified by EIA second generation kits),
2. Elevated transaminase (AST) levels with a minimum
of 7 fold the upper normal limits [13]. 3. Negative sero-
logic results for hepatitis B surface antigen (HBsAg), IgM
antibodies to hepatitis B core antigen (IgM anti-HBc)
and IgM-antibody to hepatitis A virus (HAV). After
obtaining informed consent, 54 patients were enrolled
from Abassia and 32 from Alexandria Fever hospital. The
study protocol ( NAMRU3.2004.0021) was approved by
the U.S. Naval Medical Research Unit No. 3 Institutional
Review Board and Egyptian Ministry of Health and Popu-
lation (Assurance FWA00016183) in compliance with all
applicable Federal regulations governing the protection
of human subjects.
Gender and age-matched controls (± 5 years) were
recruited from hospital visitors not living in the case-
patient households. After obtaining informed consent,
eligible controls were serologically screened for anti–
HCV, HBsAg, IgM anti-HBc, and IgM anti-HAV. Con-
trols with one or more positive of the above markers
were excluded and replaced. Three-four sero-negative
controls were recruited for each of the 86 case-patients
to allow for exclusion of controls showing one or more
positive antibodies for hepatitis viruses. Sample size esti-
mates were based on calculations to detect an odds ratio
(OR) of 3, assuming a frequency of single exposure of
25% among controls and 40% among patients, with a
power of 80% and a significance level of 5%.
Serologic testing
Serologic and AST testing was conducted at the partici-
pating hospital laboratories for case-patients; U.S. Naval
Medical Research Unit#3 (NAMRU-3) screened con-
trols. All institutions used enzyme-linked immunoassays
(ELISA) with commercial kits (Abbott Diagnostic Div-
ision) including the second generation kit for anti-HCV.
AST and ALT were tested using BIOLABO (Les Hautes
Rives, 02160 Maizy, France) kits.
Risk factors assessment
Trained social workers interviewed case-patients and
controls using a standardized questionnaire that included
demographic information, specific behaviors and activ-
ities in the 6 months prior to the case-patient hospital
admission date. The questionnaire was pilot tested by
trained interviewers.
Potential risk factors for HCV infection were categor-
ized into healthcare-associated exposures and high risk
behaviors in the community. Healthcare-associated expo-
sures were categorized into outpatient services including
type of clinic and procedures performed at outpatients
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versus hospital procedures including hospital admission
and procedures performed at hospital. Community-level
exposures included behaviors with the potential to trans-
mit blood-borne pathogens such as sharing toothbrushes
or sharp instruments, household contact with a person
with acute or chronic hepatitis, sexual contact with mul-
tiple partners and being imprisoned over the previous six
months. For each potential exposure to a risk factor, the
date, duration of exposure, and location were recorded.
Statistical analyses
Univariate and matched data analyses were done with
EPIINFO version 6.04 (EPI6). Individual matching by
gender and age (±5 years) was performed. For variables
that might influence the occurrence of acute HCV, we
calculated OR, 95% confidence interval (CI), and the
p- value.
To assess the simultaneous association between several
exposure variables and case–control status, we employed
conditional logistic regression models using SPSS ver 17.
These models were used to estimate ORs as a measure
of association to identify risk factors for HCV infection
with attention to the exposures commonly associated
with HCV transmission. Case–control status was selected
as the dependent variable, while all exposure variables
and potential confounders significantly related to case–
control status in univariate analyses with p value <0.05
were selected as independent variables in these models
In these models the coefficients for the independent
variables were exponentiated to estimate adjusted ORs,
and standard errors for the coefficients were used to
construct confidence intervals for the adjusted ORs.
Variables were removed in a stepwise fashion using a
likelihood ratio test at each step to assess their import-
ance in the model, until finally only those factors signifi-
cant at a 0.05 level remained in the model. All statistical
tests were interpreted in a two-tailed fashion to estimate
p-values and confidence intervals. The etiologic fraction
in the population (EFp) for the exposures that remained
in the module was calculated using OPENEPI calculator
software [14].
Results
Eighty-six case-patients and 287 age and gender-
matched controls were enrolled in the study; 80 controls
were excluded after serologic testing for IgM anti-HAV
(16), IgM anti-HBcAb (6), anti-HCV (56) and 2 who
were positive for both anti-HAV and anti-HBcAb. The
mean age of case-patients was 39.2 ±13.6 years, with
slight male predominance; approximately 50% of patients
were 20–39 years of age. There was no significant differ-
ence in the age, gender and distribution of occupations
among case-patients relative to controls. Case-patients
were more likely to be illiterate and report past medical
conditions than controls (Table 1). No significant (p=0.1)
difference in the risk of having the disease was found
between the subjects with history of chronic medical
conditions and those with no chronic conditions, ex-
cluding subjects who had had invasive procedures in
the previous 6 months.
Univariate analysis
At least one risk factor was detected in 80 patients;
6 patients (7%) reported they had not been exposed to any
of the potential risk factors. Several outpatient medical-
related procedures were significantly associated with
acquiring acute HCV infections, including receiving
injections with reused syringes, receiving IV fluids, min-
imal surgical procedures including abscess drainage, re-
ceiving dental care and wound stitches in an outpatient
setting (Table 2). Visiting private, urban outpatient clinics
was also associated with risk of HCV infection, whereas
attending governmental, rural outpatient clinics was not.
Although visiting a family planning clinic among females
was associated with the disease, yet the 95% CI included
1. After stratifying with attending an outpatient clinic,
only receiving IV fluid, reused syringe use and minimal
surgical procedures at an outpatient clinic remained
significant.
In-patient hospital exposures were also associated with
HCV infection, including hospitalization for any reason,
receipt of IV fluids, surgery, endoscopy, receipt of a trans-
fusion, labor for females and insertion of urinary catheters
(Table 3). Among patients and controls who were hospita-
lized in the previous six months, using t-test for compar-
ing 2 means, there was no significant difference regarding
mean number of hospital admissions (p value =0.07) and
mean length of stay at hospital (p value =0.06). Stratifying
with hospital admission, only receiving IV fluid at hos-
pital remained significant.
For community-level exposures, case-patients were more
likely to report injecting drug use and recent incarceration
than controls. Sharing toothbrushes, use of a public barber,
injury while being shaved, and receipt of injections outside
the formal health care setting were not associated with
HCV infection (Table 4).
Multivariate analysis for risk factors
Logistic regression analysis identified six independent
variables (Table 5). Factors were classified into three cat-
egories: hospital exposure, outpatient care and lifestyle-
associated practices. Variables in the multivariate model
remained significant after adjusting for occupation, edu-
cation and history of chronic diseases.
We estimated the adjusted etiologic fraction in the
population (EFp) for the six risk factors that entered the
multivariate logistic regression model (Table 5). Results
show that hospital exposures and invasive procedures
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account for the major proportion of HCV infections in
Egypt.
Discussion
For clinical diagnosis of patients with signs or symptoms
of liver disease CDC recommends testing by using anti-
HCV [15]. However anti-HCV testing detects the pres-
ence of antibodies to the virus, indicating exposure to
HCV and cannot distinguish between someone with an
active or a previous HCV infection. Before 2004 when
CDC developed a case definition for acute hepatitis, all
studies searching for HCV infection risk factors were
using anti-HCV testing to identify cases, this means that
using this case definition might not reflect the accurate
risk factors for infection because it is unclear when the
patient was exposed. This is the first study to use the
case definition developed by CDC in 2004 [13] to enroll
the acute newly infected cases to help identify accurately
the true risk factors for HCV infection.
Primary prevention of HCV infection remains the
most important strategy to prevent HCV complications.
This is particularly important due to absence of vaccine
and cost effective medical therapy. The impact of any
effort to prevent and control HCV infections relies on
accurate epidemiological data, particularly the identifi-
cation of risk factors associated with new infections.
Table 1 Demographic characteristics of the study population
Demographic
characteristics
Case patients n=86 Controls n=287 OR CI 95% P value
Mean SD Mean SD
age in years 39.2 (± 13.6) 37.6 (± 12.4) 0.97 1.6-4.8 0.3
No. % No. %
Age groups:
< 20 2 2 8 3 0.8 0.1-4.3 0.8
20-29 23 27 77 27 1 0.6-1.8 0.9
30-39 19 22 82 28 0.7 0.4-1.3 0.3
40-49 22 26 65 23 1.2 0.7-2.1 0.7
50-59 14 16 42 15 1.1 0.6-2.3 0.7
60-69 6 7 13 4 1.6 0.5-4.7 0.4
Male 51 59 164 57 1.1 0.7-1.8 0.7
*Marital status
Single 19 22 81 28 0.7 0.4-1.3 0.3
Married 67 78 205 72 1.4 0.8-2.6 0.2
**Education
Illiterate 63 81 155 56 2.3 1.3-4.1 0.001
Educated 15 19 121 44 0.3 0.3-0.6 0.0000
Occupation
Worker 17 20 60 20 0.9 0.5-1.8 0.8
Soldier 2 2 0 0 NA NA NA
Student 2 2 5 2 1.3 0.2-8 0.7
Employee 6 7 42 15 0.4 0.2-1.1 0.06
Medical 0 0 13 5 NA NA NA
Unemployed 33 38 106 37 1.1 0.6-1.8 0.8
Others 26 30 61 21 1.6 0.9-2.9 0.08
History of chronic illnesses
Diabetes 10 12 32 12 1.1 0.5-2.3 0.9
Schistosomiasis 6 7 12 4 1.7 0.6-5.7 0.3
Hypertension 16 19 28 10 2.1 1.1-4.3 0.02
Hepatomegaly 5 6 0 0 NA NA NA
Spleenomegaly 2 2 0 0 NA NA NA
Cirrhosis 0 0 2 1 NA NA NA
Gall stones 21 24 39 14 2.1 1.1-3.9 0.02
* data missing for one control.
** data missing for 8 cases and 11 controls.
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Egypt, like other countries with a similar disease burden,
have limited funds to support wide-scale prevention pro-
grams. Therefore, targeting and prioritizing prevention
activities are essential [12].
Most seroprevalence studies in Egypt suggest
community-acquired practices account for the bulk of
HCV transmission in Egypt [16]. This has lead to consid-
erable investment in communication strategies directed
at the public to promote behavior changes to decrease
sharing razors and toothbrushes, getting tattoos and
other risky behaviors. Identifying current risk factors for
ongoing HCV transmission is challenging, as most HCV
infections are initially asymptomatic and available assays
do not distinguish acute from chronic or resolved infec-
tions. The US Centers for Disease Control and Prevention
(CDC), in association with the Council of State and Terri-
torial Epidemiologists (CSTE), recently developed a case
definition for acute hepatitis C to differentiate between
recent infections, old infections and disease exacerbation
[13]. The publication of this case definition encouraged
us to conduct a case control study to explore risk factors
for HCV infection among patients meeting the case
definition of acute disease. Other methods to identify
patients with newly acquired HCV infection include
identification of patients who seroconvert from negative
to positive anti-HCV antibody. Cohort studies have iden-
tified such patients in village-based studies. However, the
number of patients is small and the ability to identify risk
factors that are generalizable has been limited [17].
The findings from this study highlight the importance
of health care exposures as a source of ongoing HCV
transmission in Egypt. The findings suggest both out-
patient procedures and as well as exposures within the
hospital play a role in transmission. The risks in the out-
patient settings are apparent, particularly if providers re-
use injection equipment e.g. syringes and IV line. Of
particular concern is the apparent break in standard pre-
cautions during minor procedures such as administra-
tion of IV fluids, suturing, and conducting minimal
surgeries. This suggests that primary care staff lack the
basic skills for using safe procedures such as the use of
aseptic techniques, or it could be due to a shortage of
Table 2 Outpatient related risk factors (within 6 months) associated with transmission of acute hepatitis C virus
infection, Abbassia and Alexandria Fever Hospitals, Egypt
Exposure Cases n=86 Controls n=287 OR 95% Cl P value
No % No %
Receiving injections 27 31 54 19 2 1.1-3.5 0.008
Receiving injection with a reused syringe 12 14 2 1 23.1 4.7-153 < 0.000
Receiving IV fluids 30 35 18 6 8 4-16.2 < 0.000
Minimal surgical procedures (draining abscess
and suturing wounds)
24 28 11 4.3 9.7 4.2-22.4 < 0.000
Visiting outpatient clinic for all causes 73 85 183 64 2.3 1.6-6.4 < 0.000
Visiting a private outpatient clinic 45 52 92 32 2.3 1.4-4 < 0.000
Visiting a rural outpatient clinic 3 3 4 1 2.5 0.4-13.8 0.1
Visiting a governmental outpatient clinic 19 22 63 22 1 0.5-2 0.5
Visit urban outpatient clinic 70 81 176 61 2.8 1.5-5.2 < 0.000
Visiting a family planning clinic (females only) 8/35 24 13/124 11 2.4 0.8-7.1 0.04
Visiting a dental outpatient clinic 28 33 61 21 1.7 1-3.2 0.02
Table 3 Hospital-related risk factors associated with transmission of acute hepatitis C virus infection, Abbassia and
Alexandria Fever Hospitals, Egypt
Exposure Cases n=86 Controls n=287 OR 95% Cl P value
No % No %
Hospital admission 36 42 24 8 7.9 4.2-15 < 0.000
Receiving IV Fluid 22 26 7 2 13.8 5.3-37.2 < 0.000
Receive invasive procedure during
hospitalization
22 27 14 5 6.7 3.1-14.7 < 0.000
Surgery 16 19 9 3 7.1 2.8-18.2 < 0.000
Endoscopy 5 6 3 1 5.8 2.1-31.6 0.01
Labor (for females) 5 / 35 16 5 /124 4 4 1.1-11.6 0.03
Insertion of urinary catheter 4 5 2 1 6.9 1.1-55.6 0.02
Receiving blood transfusion 7 8 2 1 12.6 2.3-89.8 < 0.000
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supplies. In this study, outpatient dental care was not
found to be strongly associated with HCV infection.
Population-based or larger case–control studies are
needed before any firm conclusions can be inferred
regarding the role of dental care and HCV transmission.
The possibility of acquiring acute HCV infections
through hospitalization for any cause has been the sub-
ject of intense study [18-20], particularly in developing
countries. The rapid introduction of new technologies and
invasive procedures in settings without well-developed in-
fection control programs provides a unique ecologic niche
for HCV transmission [19]. This is particularly problem-
atic in countries like Egypt where the prevalence of HCV
infection among hospitalized patients is high and minor
lapses in standard precautions can expose health care
workers and patients to HCV-infected blood or body
fluids [21].
In this study, we observed that several invasive proce-
dures were associated with acquiring new HCV infec-
tions. Prior studies have identified surgery or invasive
medical procedures as main risk factors associated with
transmission of HCV infection in developed countries
[20,22]. In a case–control study in Italy, Mele et al. iden-
tified an invasive procedure within 6 months of acute
HCV infection onset in 25% of the patients [23].
The association of HCV infection with endoscopy com-
bined with interventional procedures such as biopsies or
scelerotherapy, has also been described [24]. In a 1994–
1999 study performed by the Italian National Hepatitis
Surveillance System [23], endoscopy had been performed
in 4.6% of the patients with acute HCV infection and the
estimated OR for endoscopy was 2.1 (95% CI, 1.2–3.6).
This has implications for Egypt, due to the high number
of patients with chronic hepatitis from schistosomiasis
and chronic hepatitis B requiring endoscopy. Risk of
transmission of HCV through endoscopy is easily elimi-
nated when the recommended cleansing, decontamin-
ation and sterilization procedures are followed [25-27].
In addition to exposures in the health care setting, this
study also identified injection drug use as an independent
risk factor for HCV infection. In the developed world,
there is accumulated evidence that injection drug use is
the predominant source of new HCV infections over the
past few decades which accounts for 68% and 80% of
current infections [2,28,29]. While this study also high-
lights the role of injecting drug use as a risk factor for
HCV infection in Egypt, the percentage of patients
reporting injection drug use (23%) is considerably low in
comparison to developed countries. Egypt is among the
African countries that recently reported experiencing
Table 4 Lifestyle related risk factors associated with transmission of HCV
Exposure Cases n=86 Controls n=287 OR 95% confidence
limit
P value
No % No %
Being imprisoned 6 7 1 0.3 21.5 2.5-479.6 < 0.000
Injecting drug use 20 23 7 2 12.1 4.6-33.1 < 0.000
Sharing tooth brushes 8 9 15 5 1.9 0.9-4.9 0.09
Shaving at a barber shop (for males) 50 / 51 98 157 / 163 96 1.9 0.2-43.1 0.3
Wounded at barber 21 /51 41 70 / 163 43 0.9 0.5 – 1.8 0.4
Receiving injections outside healthcare
settings (home or pharmacy)
24 28 86 30 0.9 0.5-1.6 0.4
Table 5 Multivariate analysis module
Risk factors OR CI a EFp b CI c
Hospital exposures
Receipt of IV fluids 13.7 5.6-33.5 70.3 51.2-89.5
Hospital admission 7.8 4.3-14.3 52.4 37.5-67.3
Invasive procedures d 4.7 2.8-7.9 35.1 23.7-46.5
Outpatient care
Abscess drainage 33.4 4.2-267.9 87.3 63.7-100
Receiving injection with a Reused syringes 23.1 4.7-153 82 58.9-100
Lifestyle-associated
IV drug user 12.1 4.9-29.8 67.9 47.5-88.5
a Confidence interval for the odds Ratio.
b EFp is the etiologic fraction in the population.
c Confidence interval for the etiologic fraction in the population.
d Invasive procedures include minimal surgical procedures at outpatients and procedures at hospital.
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injection drug use. Little information regarding drug use
is available in Egypt not only because it is relatively new,
but also because of the lack of funds to monitor it in a
systematic way [30]. This study also found that incarcer-
ation six months prior to start of illness was also a risk
factor for disease. Further studies are needed to identify
the specific source of HCV infection among incarcerated
persons.
We did not identify any evidence of occupational or
sexual risk factors associated with HCV transmission in
Egypt. Numerous studies suggest that HCV transmission
through occupational and sexual exposures is inefficient
and that these exposures are unlikely to be major sources
of new HCV infections, regardless of the population or
geographic location [2].
Egypt is now experiencing a wave of HCV-related
morbidity with increasing numbers of patients with end
stage cirrhosis or hepatocellular carcinoma. The cost of
treatment or liver transplantation is a strain on the na-
tional health care budget. Many patients are presenting
at the peak of their productive lives with considerable
impact on their families and community. Preventing on-
going transmission is of paramount importance to the
health of future generations. Therefore, national strat-
egies should focus on primary prevention by reducing
the numbers of new infections. Ideally, successful treat-
ment of infected patients has the potential to help reduce
the incidence of HCV infection by decreasing the reser-
voir of infected persons who can serve as a source of
transmission [10]. However, in Egypt the burden of dis-
ease is high and the capacity to treat large numbers of
patients to reduce viral load is limited. This may reduce
the possibility of having a meaningful impact on the res-
ervoir of HCV-infected people in Egypt through treat-
ment regimens.
Limitations of the study include selection of controls
from the hospital visitors of the enrolled case patients
or other patients in the same hospital; this may lead to
selection bias because the cases and controls were not
matched by place of residence.
Conclusion
The results of this study show that a number of newly
identified risk factors are contributing to HCV transmis-
sion in Egypt. As HCV prevention remains a major chal-
lenge, and due to limited resources, activities to stop
transmission should focus on safe practices in the health-
care setting. A national program to promote infection
control has been implemented in Ministry of Health
Hospitals since 2002, which was expanded to all general
and district hospitals (356 hospitals). They have plans to
expand further to primary care hospitals and units [31].
However, the healthcare system in Egypt is huge and
complex and requires human and financial resources to
strengthen infection control programs in settings where
they exist and expand them to involve all healthcare
institutions in Egypt, such as university, private, military
hospitals and others. Empowering community members
to refuse unsafe medical procedures could be implemen-
ted. Special attention to institutionalizing infection con-
trol programs in primary outpatient care settings is also
essential.
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